Professional Documents
Culture Documents
Tolmar
Tolmar
EVIDENCE1
.
SHOULD
BE
0 7 YOUR GOAL
nmol/L
ELIGARD is indicated for the palliative treatment of advanced prostate cancer.2 ELIGARD with over 10 years experience in the LHRH
(leutinising hormone-releasing hormone) therapy across all dose forms.2 *European Association of Urology recommends a more
appropriate castration level defined as <0.7 nmol/L but the castration level considered by the regulatory authorities is still 1.7 nmol/L.1
Eligard is a registered trademark of TOLMAR Therapeutics, Inc. Full Product Information is available from: TOLMAR Australia Pty Ltd.
ABN 53 162 640 708. Level 2/20 Bridge St, Pymble, NSW 2073. Ph: 1800 TOLMAR (865 627). TOLHTSI210616.
Date of approval: August 2016. TOL0068.